Cargando…

Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach

Chemotherapy is the mainstream treatment modality for invasive breast cancer. Unfortunately, chemotherapy-associated adverse events can result in early termination of treatment. Paradoxical effects of chemotherapy are also sometimes observed, whereby prolonged exposure to high doses of chemotherapeu...

Descripción completa

Detalles Bibliográficos
Autores principales: Tai, Yee Kit, Chan, Karen Ka Wing, Fong, Charlene Hui Hua, Ramanan, Sharanya, Yap, Jasmine Lye Yee, Yin, Jocelyn Naixin, Yip, Yun Sheng, Tan, Wei Ren, Koh, Angele Pei Fern, Tan, Nguan Soon, Chan, Ching Wan, Huang, Ruby Yun Ju, Li, Jing Ze, Fröhlich, Jürg, Franco-Obregón, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818958/
https://www.ncbi.nlm.nih.gov/pubmed/35141145
http://dx.doi.org/10.3389/fonc.2021.783803
_version_ 1784645948720283648
author Tai, Yee Kit
Chan, Karen Ka Wing
Fong, Charlene Hui Hua
Ramanan, Sharanya
Yap, Jasmine Lye Yee
Yin, Jocelyn Naixin
Yip, Yun Sheng
Tan, Wei Ren
Koh, Angele Pei Fern
Tan, Nguan Soon
Chan, Ching Wan
Huang, Ruby Yun Ju
Li, Jing Ze
Fröhlich, Jürg
Franco-Obregón, Alfredo
author_facet Tai, Yee Kit
Chan, Karen Ka Wing
Fong, Charlene Hui Hua
Ramanan, Sharanya
Yap, Jasmine Lye Yee
Yin, Jocelyn Naixin
Yip, Yun Sheng
Tan, Wei Ren
Koh, Angele Pei Fern
Tan, Nguan Soon
Chan, Ching Wan
Huang, Ruby Yun Ju
Li, Jing Ze
Fröhlich, Jürg
Franco-Obregón, Alfredo
author_sort Tai, Yee Kit
collection PubMed
description Chemotherapy is the mainstream treatment modality for invasive breast cancer. Unfortunately, chemotherapy-associated adverse events can result in early termination of treatment. Paradoxical effects of chemotherapy are also sometimes observed, whereby prolonged exposure to high doses of chemotherapeutic agents results in malignant states resistant to chemotherapy. In this study, potential synergism between doxorubicin (DOX) and pulsed electromagnetic field (PEMF) therapy was investigated in: 1) MCF-7 and MDA-MB-231 cells in vitro; 2) MCF-7 tumors implanted onto a chicken chorioallantoic membrane (CAM) and; 3) human patient-derived and MCF-7 and MDA-MB-231 breast cancer xenografts implanted into NOD-SCID gamma (NSG) mice. In vivo, synergism was observed in patient-derived and breast cancer cell line xenograft mouse models, wherein PEMF exposure and DOX administration individually reduced tumor size and increased apoptosis and could be augmented by combined treatments. In the CAM xenograft model, DOX and PEMF exposure also synergistically reduced tumor size as well as reduced Transient Receptor Potential Canonical 1 (TRPC1) channel expression. In vitro, PEMF exposure alone impaired the survival of MCF-7 and MDA-MB-231 cells, but not that of non-malignant MCF10A breast cells; the selective vulnerability of breast cancer cells to PEMF exposure was corroborated in human tumor biopsy samples. Stable overexpression of TRPC1 enhanced the vulnerability of MCF-7 cells to both DOX and PEMF exposure and promoted proliferation, whereas TRPC1 genetic silencing reduced sensitivity to both DOX and PEMF treatments and mitigated proliferation. Chronic exposure to DOX depressed TRPC1 expression, proliferation, and responses to both PEMF exposure and DOX in a manner that was reversible upon removal of DOX. TRPC1 channel overexpression and silencing positively correlated with markers of epithelial-mesenchymal transition (EMT), including SLUG, SNAIL, VIMENTIN, and E-CADHERIN, indicating increased and decreased EMT, respectively. Finally, PEMF exposure was shown to attenuate the invasiveness of MCF-7 cells in correlation with TRPC1 expression. We thus demonstrate that the expression levels of TRPC1 consistently predicted breast cancer sensitivity to DOX and PEMF interventions and positively correlated to EMT status, providing an initial rationale for the use of PEMF-based therapies as an adjuvant to DOX chemotherapy for the treatment of breast cancers characterized by elevated TRPC1 expression levels.
format Online
Article
Text
id pubmed-8818958
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88189582022-02-08 Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach Tai, Yee Kit Chan, Karen Ka Wing Fong, Charlene Hui Hua Ramanan, Sharanya Yap, Jasmine Lye Yee Yin, Jocelyn Naixin Yip, Yun Sheng Tan, Wei Ren Koh, Angele Pei Fern Tan, Nguan Soon Chan, Ching Wan Huang, Ruby Yun Ju Li, Jing Ze Fröhlich, Jürg Franco-Obregón, Alfredo Front Oncol Oncology Chemotherapy is the mainstream treatment modality for invasive breast cancer. Unfortunately, chemotherapy-associated adverse events can result in early termination of treatment. Paradoxical effects of chemotherapy are also sometimes observed, whereby prolonged exposure to high doses of chemotherapeutic agents results in malignant states resistant to chemotherapy. In this study, potential synergism between doxorubicin (DOX) and pulsed electromagnetic field (PEMF) therapy was investigated in: 1) MCF-7 and MDA-MB-231 cells in vitro; 2) MCF-7 tumors implanted onto a chicken chorioallantoic membrane (CAM) and; 3) human patient-derived and MCF-7 and MDA-MB-231 breast cancer xenografts implanted into NOD-SCID gamma (NSG) mice. In vivo, synergism was observed in patient-derived and breast cancer cell line xenograft mouse models, wherein PEMF exposure and DOX administration individually reduced tumor size and increased apoptosis and could be augmented by combined treatments. In the CAM xenograft model, DOX and PEMF exposure also synergistically reduced tumor size as well as reduced Transient Receptor Potential Canonical 1 (TRPC1) channel expression. In vitro, PEMF exposure alone impaired the survival of MCF-7 and MDA-MB-231 cells, but not that of non-malignant MCF10A breast cells; the selective vulnerability of breast cancer cells to PEMF exposure was corroborated in human tumor biopsy samples. Stable overexpression of TRPC1 enhanced the vulnerability of MCF-7 cells to both DOX and PEMF exposure and promoted proliferation, whereas TRPC1 genetic silencing reduced sensitivity to both DOX and PEMF treatments and mitigated proliferation. Chronic exposure to DOX depressed TRPC1 expression, proliferation, and responses to both PEMF exposure and DOX in a manner that was reversible upon removal of DOX. TRPC1 channel overexpression and silencing positively correlated with markers of epithelial-mesenchymal transition (EMT), including SLUG, SNAIL, VIMENTIN, and E-CADHERIN, indicating increased and decreased EMT, respectively. Finally, PEMF exposure was shown to attenuate the invasiveness of MCF-7 cells in correlation with TRPC1 expression. We thus demonstrate that the expression levels of TRPC1 consistently predicted breast cancer sensitivity to DOX and PEMF interventions and positively correlated to EMT status, providing an initial rationale for the use of PEMF-based therapies as an adjuvant to DOX chemotherapy for the treatment of breast cancers characterized by elevated TRPC1 expression levels. Frontiers Media S.A. 2022-01-24 /pmc/articles/PMC8818958/ /pubmed/35141145 http://dx.doi.org/10.3389/fonc.2021.783803 Text en Copyright © 2022 Tai, Chan, Fong, Ramanan, Yap, Yin, Yip, Tan, Koh, Tan, Chan, Huang, Li, Fröhlich and Franco-Obregón https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Tai, Yee Kit
Chan, Karen Ka Wing
Fong, Charlene Hui Hua
Ramanan, Sharanya
Yap, Jasmine Lye Yee
Yin, Jocelyn Naixin
Yip, Yun Sheng
Tan, Wei Ren
Koh, Angele Pei Fern
Tan, Nguan Soon
Chan, Ching Wan
Huang, Ruby Yun Ju
Li, Jing Ze
Fröhlich, Jürg
Franco-Obregón, Alfredo
Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach
title Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach
title_full Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach
title_fullStr Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach
title_full_unstemmed Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach
title_short Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach
title_sort modulated trpc1 expression predicts sensitivity of breast cancer to doxorubicin and magnetic field therapy: segue towards a precision medicine approach
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818958/
https://www.ncbi.nlm.nih.gov/pubmed/35141145
http://dx.doi.org/10.3389/fonc.2021.783803
work_keys_str_mv AT taiyeekit modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach
AT chankarenkawing modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach
AT fongcharlenehuihua modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach
AT ramanansharanya modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach
AT yapjasminelyeyee modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach
AT yinjocelynnaixin modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach
AT yipyunsheng modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach
AT tanweiren modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach
AT kohangelepeifern modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach
AT tannguansoon modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach
AT chanchingwan modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach
AT huangrubyyunju modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach
AT lijingze modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach
AT frohlichjurg modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach
AT francoobregonalfredo modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach